The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A16 | Other alimentary tract and metabolism products | |
| 3 | A16A | Other alimentary tract and metabolism products | |
| 4 | A16AB | Enzymes | |
| 5 | A16AB23 |
| Active Ingredient | Description | |
|---|---|---|
| Cipaglucosidase alfa |
Sipaglucosidase alfa is intended to replace the endogenous enzyme acid-alpha-glucosidase (GAA) that breaks down glycogen to glucose in the lysosome and is absent or impaired in Pompe disease. Sipaglucosidase alfa exerts enzymatic activity in the breakdown of glycogen and the reduction of intramuscular glycogen, as well as the amelioration of tissue damage. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| POMBILITI Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
